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The volume of hip arthroplasty is stiffly increasing because of excellent clinical outcomes, however it has not
been shown to decrease the incidence of transfusions due to bleeding related to this surgery. This is an important
consideration since there are concerns about the side effects and social costs of transfusions. First, anemia should
be assessed at least 30 days before elective hip arthroplasty, and if the subject is diagnosed as having anemia, an
additional examination of the cause of the anemia should be carried and steps taken to address the anemia.
Available iron treatments for anemia take 7 to 10 days to facilitate erythropoiesis, and preoperative iron
supplementation, either oral or intravenous, is recommended. When using oral supplements for iron storage,
administer elemental iron 100 mg daily for 2 to 6 weeks before surgery, and calculate the dose using intravenous
supplement. Tranexamic acid (TXA) is a synthetic derivative of the lysine component, which reduces blood loss
by inhibiting fibrinolysis and clot degradation. TXA is known to be an effective agent for reducing postoperative
bleeding and reducing the need for transfusions in primary and revision total hip arthroplasties. Patient blood
management has improved the clinical outcome after hip arthroplasty through the introduction and research of
various agents, thereby reducing the need for allogeneic blood transfusions and reducing the risk of transfusion-
related infections and the duration of hospitalizations.
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INTRODUCTION
Among surgical techniques introduced in the 20th century,
hip arthroplasty has demonstrated some of the best treatment
results and its use is becoming more frequent as the population
ages. However, a considerable amount of blood loss is
unavoidable during hip arthroplasty. Park et al.1) have
reported that approximately 1,500 mL of blood is lost
during the surgery. Even though knowledge is increasing
and blood management techniques are gradually progressing,
the incidence of allogeneic blood transfusions in the field
of orthopedics has not decreased. Considering the side effects
and social costs of transfusions (e.g., immune suppression,
acute and delayed hemolytic reaction, anaphylaxis, transfusion-
related acute lung injury, host response and postoperative
infection), studies on the needs and methods of patient blood
management are warranted.
The authors of this study reviewed recent published methods
designed to minimize bleeding and transfusion and guidelines
for appropriate transfusion protocols during hip arthroplasty.
PREOPERATIVE ANEMIA ASSESSMENT
Even mild degree of anemia can contribute to the risk
for postoperative transfusions and mortality rates in hip
surgery2). Therefore, the presence of anemia should be
evaluated at least 30 days before surgery in patients
undergoing hip surgery3). When a patient is diagnosed with
anemia, an additional examination should be carried out
to determine the cause of the anemia and to correct this
condition, and surgery should be postponed until the anemia
is resolved3). For preoperative evaluation, detailed history
taking, including gastrointestinal-related symptoms especially
in elderly patients, and assessment of complete blood
count (CBC), iron studies including ferritin, C-reactive
protein, renal function and others is required.
Serum hemoglobin is the level of hemoglobin in the
blood and measured in g/dL (normal ranges, male: 13-
17 g/dL, female: 12-15 g/dL), and hematocrit measures
the percentage (%) of red blood cells (RBC) in the serum
(normal ranges, male: 39-50%, female: 36-45%). Among
RBC indices, the mean corpuscular volume (MCV) is a
measure of the average volume of a RBC in femtoliter
(fL) (normal range, 62-96 fL) and the mean corpuscular
hemoglobin (MCH) is the average amount of hemoglobin
per RBC and the unit of measurement is picogram (pg;
normal range, 20-31pg). The mean corpuscular hemoglobin
concentration (MCHC) is the average concentration of
hemoglobin in RBCs. The MCHC is often decreased in
microcytic anemia, mostly normal in macrocytic anemia,
and elevated in hereditary spherocytosis or sickle cell
disease (normal range, 27-38 g/dL).
Tests for iron studies include CBC, peripheral smear, serum
iron, total iron binding capacity (TIBC), serum ferritin,
reticulocyte hemoglobin content and others. Ferritin is a
universal intracellular protein that stores iron and releases it in
a controlled fashion. Normal ferritin levels range between 15-
200 ng/mL (males) and 12-150 ng/mL (females). A decrease
in serum ferritin is the most specific lab test to determine iron-
deficiency anemia. A low preoperative hemoglobin level
before surgery is an independent risk factor of transfusion,
and in cases of malnutrition, insufficient nutrients need to be
supplemented4). The goal of correction before surgery is to
elevate hemoglobin concentration to normal levels
established by the World Health Organization3,5). Since
erythropoiesis takes about 7-10 days, oral or intravenous
(IV) iron supplementation is recommended for preoperative
iron supplementation in cases of iron deficiency3). When
using oral supplements for iron storage, a daily dose of
100 mg elemental iron is recommended for 2 to 6 weeks
before surgery. When using IV iron supplementation,
requirements can be estimated using the Ganzoni equation
below6).
Total iron deficit (mg)=[target Hb–actual Hb (mg/dL)]
×weight (kg)×0.24+500 mg
The dose of iron supplementation used for treatment
purpose should be adjusted according to the formulations
of iron supplements administered.
The best way to prevent postoperative anemia and the
need for transfusion is to screen and correct anemia before
surgery. The diagnosis and correction of anemia are very
important because 74% of patients undergoing surgery
experience anemia before and after surgery7).
Since surgical manipulations induce inflammatory responses
and inhibit erythropoiesis, oral iron supplementation after
surgery is ineffective and generates side effects8). For this
reason, IV iron supplementation is recommended to correct
postoperative anemia and prevent transfusion following
surgery3).
The recommended dosage of IV iron supplementation
after surgery is a dose of 200 mg of elemental iron per 500
mL of blood loss3). Since IV iron supplementation increases
the risk of hypersensitivity reactions, it is recommended that
this form of supplementation is administered in a clinical
setting capable of managing anaphylactic or anaphylactoid
reaction9). Thus, patients need to be thoroughly monitored
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for 30 minutes after completion of IV iron supplementation9).
In addition, iron supplements should be given in accordance
with administration instructions written on product labels.
Preoperative erythropoietin can be used for adults who
deposit more than 3 units of whole blood through pre-deposit
program prior to hip surgery or for those who cannot pre-
deposit despite of an estimated blood loss of greater than
1,000 mL intraoperatively3). For patients requiring facilitated
production of maximum RBCs, IV administration is
recommended at a dose of 600 IU/kg twice a week for 3
weeks. To prevent the reduction of iron stores associated
with the use of erythropoietin, IV iron supplementation
is advised10,11).
STRATEGY TO MINIMIZE BLOOD LOSS
Preoperative tests for bleeding tendencies in patients
should be performed. When patients have risk factors
for anemia or intraoperative bleeding, surgeons should
correct bleeding tendencies in order to avoid unexpected
bleeding. Preoperative anemia is a risk factor that increases
postoperative morbidity and mortality, and is known as a
cause of iron deficiency in more than 1/3 of cases12,13). After
evaluating the conditions and causes of anemia according
to serum hemoglobin and ferritin concentrations, correction
of anemia status is recommended from 4 weeks prior to
surgery using iron, vitamin B12, folic acid, erythropoietin
and others14-16). Adjustment of antiplatelet or anticoagulant
agents such as aspirin, heparin, warfarin and clopidogrel
are suggested for reducing intra- and post-operative
bleeding. Furthermore, the possibility of transfusion caused
by unexpected bleeding and associated complications can
be lowered by determining family history of coagulopathy
or presence of liver disease17-21). Although preoperative
autologous blood donation is not thought to be cost effective
and does not lower transfusion rates, it is considered as
an option for those patients with rare blood types22).
Since inappropriate positioning during surgery may
influence intraoperative bleeding by generating venous
engorgement, surgical positioning should be carefully
considered and implemented. Moreover, the pressure and
tidal volume of ventilator should be adjusted to decrease
the mean intrathoracic pressure because positive pressure
ventilation under general anesthesia may have an adverse
effect on venous return23).
Since intraoperative hypothermia may increase bleeding
by reducing platelet function and enzyme activity in the
coagulation cascade, the maintenance of normal body
temperature is required24). Controlled hypotension technique
reduces blood loss by decreasing blood extravasation and
local wound blood flow, but consistent hemodynamic
monitoring is required and this technique is not permitted
in patients with coronary artery disease25).
Central neuraxial blocks such as spinal and epidural
anesthesia are known to have blood saving effects by
decreasing sympathetic tone and venous tone, and their
effects last until postoperative period1,26-28). Local anesthesia
can reduce the need for transfusion and complication rates
(e.g., postoperative mortality, thromboembolic events,
pneumonia, respiratory depression, myocardial infarction,
renal dysfunction)27).
Intraoperative shed blood can be collected and processed
for re-use using RBC salvage and reinfusion system23). Cell
saver, one intraoperative auotologous transfusion technique
in which drained blood is collected, washed, and reinjected,
can also be considered. Cell saver is a reinjection technique
in which the drained blood is filtered to remove hemolyzed
cells, free hemoglobin and other impurities and washed
for reinjection29,30). The use of cell saver protects patients
and decreases the need for total RBC transfusions since
the patient’s own blood is being transfused by collecting
intraoperative blood loss31).
The early diagnosis and treatment of intraoperative
coagulopathy is crucial in order to reduce blood loss. Point-
of-care testing appears to be useful for early diagnosis
because several hemostasis-related factors can be identified
at the bed side; fresh frozen plasma or fibrinogen concentrate
can be used for treatment as needed23).
The administration method and intraarticular injection of
tranexamic acid (TXA) can significantly reduce bleeding
volume32). In addition to TXA, the appropriate use of topical
hemostasis agents can also be effective at reducing bleeding.
TRANEXAMIC ACID
TXA is one of the most important agents among a
variety of intraoperative blood management protocols33,34).
TXA is a synthetic derivative of the lysine component,
and was discovered in 1962 by two independent research
groups35,36). This agent reduces blood loss by inhibiting
fibrinolysis and clot degradation. Intraoperative surgical
trauma generates fibrinolysis and elevated fibrinolytic
activity increases bleeding volume37). TXA inhibits the
interaction of protease and activated plasmin on the surface-
binding sites of fibrin by competitively and reversibly
binding to the lysine-binding sites of plasminogen. This
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mechanism blocks plasmin-induced degradation of the
fibrin clot (Fig. 1). As documented by several authors, the
use of TXA effectively and safely reduces the amount of
postoperative bleeding and the need for transfusions in
primary total hip arthroplasty and revision hip arthroplasty38-46).
However, the appropriate route (IV versus topical), correct
dose and time of administration of TXA still remain unclear.
Though a larger number of studies on IV administration
of TXA in hip arthroplasty have been reported, a recent
meta-analysis has revealed that the mean transfusion
rate was 2.56 times lower than the non-TXA group and
that the incidence of venous thrombosis was comparable
among these two groups47,48). A variety of previous studies
have suggested correct dose, administration time, frequency,
etc; the general usage is as follows:
In IV TXA administration for total hip arthroplasty, 10-20
mg/kg or 1 g of TXA is given immediately before surgery39).
Due to the pharmacokinetic properties of TXA, at least one
IV administration is recommended postoperatively49). For
topical TXA use, doses of higher than 2 g are more effective
than low-doses39). A comprehensive analysis of systematic
reviews and meta-analyses has not suggested that either
IV or topical administration of TXA generates postoperative
systemic thrombosis. However, recent clinical studies on
the use of TXA in total hip arthroplasty have provided
insufficient evidence on serious complications38).
HEMOSTATIC MEDICAL DEVICES
Appropriate surgical techniques and minimally invasive
approaches are fundamentally important to minimize
intraoperative blood loss. Although suture, Bovie, clips and
others are primarily used for hemostasis, hemostatic agents
are used as adjuvants when hemostasis fails with primary
methods50).
Hemostatic agents are mainly divided into systemic and
topical agents. Systemic hemostatic agents include lysine
analog, protease inhibitor, aprotinin and others. Since one
potential adverse event related to the use of these agents
is the systemic activation of hemostatic factors, some
Fig. 1. Schematic representation of the mechanism of action of tranexamic acid. (A) Activation of fibrinolysis. (B) Inhibition of
fibrinolysis. Due to structural similarity of lysine, tranexamic acid competitively inhibits binding of fibrin to plasminogen.
A B
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authors have described that the morbidity of cardiovascular
disease, mortality, and long-term mortality may increase51).
Efficacy, safety, fast adsorption to the tissues, absorbability,
biocompatibility and ease-of-manipulation are required for
topical hemostatic agents to be used at bleeding sites, and
hemostatic agents having no side effects such as infection
should be used.
Topical hemostatic agents are mainly divided into the
following groups: i) mechanical, ii) chemical, iii) physical,
and iv) physiological depending on their compositions and
mechanisms52). Physical agents include bone wax, Ostene
and others, and they limit blood loss by forming a physical
barrier that compresses the bleeding site. Physical agents
are commonly used as a primary option because of their cost
effectiveness.
Chemical agents are caustic substances composed of zinc,
silver nitrate or aluminum chloride. These agents precipitate
proteins necessary for hemostasis and facilitate blood
coagulation by blocking small vessels and producing thrombi
by destroying adjacent tissues.
Physical agents include gelatin, cellulose, microfibrillar
collagen and hydrophilic polymer. These hemostats induce
hemostasis by facilitating thrombus formation by forming
a three-dimensional meshwork where platelets aggregate
to form a clot. Furthermore, their hygroscopic property leads
to the accumulation of coagulation factors by absorbing blood.
Physiologic agents promote hemostasis by activating the
coagulation cascade that naturally occurs at the vasoconstriction
and bleeding sites. Physiologic agents can be based on
pharmacology (e.g., epinephrine, TXA) or natural biology
(e.g., thrombin, fibrin).
CURRENT CONSENSUS FOR APPROPRIATE
AND SAFE TRANSFUSION AFTER HIP SURGERY
Pre- and post-operative anemia is very common, and “the
10/30 transfusion trigger rule” was empirically applied in
the past. Transfusion is given when there is a transfusion
trigger (i.e., hemoglobin level below 10 g/dL or a hematocrit
level below 30%). However, this rule does not always apply
in clinical practice since it is outdated and lacks clear evidence.
Carson et al.53) suggested that there is no need to use this
conventional rule since there was no difference in mortality
and morbidity of cardiovascular disease between a group of
patients undergoing transfusions at hemoglobin levels of
less than 10 g/dL compared with those undergoing transfusions
at a hemoglobin level of 8 g/dL.
According to the National Institute For Health and
Fig. 2. Platelet activation system. ADP: adenosine diphosphate.
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Clinical Excellence (NICE) guidelines, an RBC transfusion
should be considered when hemoglobin levels are less than
7 g/dL; transfusions are also permitted in patients with
cardiovascular disease if their hemoglobin concentration is
less than 8 g/dL. However, patients with chronic anemia
should be assessed individually. Platelet transfusion is
considered for patients who are associated with severe
bleeding or a platelet count of less than 50×109/L and
undergoing surgery expected to have blood loss. Fresh frozen
plasma should only be used to replace a single coagulation
factor deflciency when abnormal findings are confirmed in
coagulation tests and heavy bleeding occurs.
DRUGS THAT INCREASE BLEEDING RISK
Blood vessel coagulation involves the exposure of
subendothelial collagen or von Willebrand factor following
vessel injury and the subsequent activation of platelets
circulating in the injured area, and eventually vasoconstriction
and platelet aggregation (Fig. 2). Medications that may increase
bleeding risks include anticoagulants, antiplatelet, novel oral
anticoagulants, non-steroidal anti-inflammatory drugs
(NSAIDs), selective norepinephrine reuptake inhibitors (SNRI)
and selective serotonin reuptake inhibitors (SSRI) (Table 1).
Anticoagulants inhibit thrombosis by activating clotting
mechanism on different areas; common anticoagulants
include heparin, hirudin, warfarin and drotrecogin alfa.
Thrombolytic agents degrade fibrinogen and fibrin and
increase the conversion of plasminogen to plasmin, thus
removing blood clots. The most common thrombolytic
drugs are anistreplase, streptokinase, urokinase, tissue
plasminogen activators (tPAs) (Fig. 3). Common antiplatelet
Table 1. Classification of Drug that Increase Bleeding Risk
Drug class Specific agents
Anticoagulants Argatroban, bivalirudin, desirudin, heparin, lepirudin, warfarin
Antiplatelets Aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine
NOAs Apixaban, dabigatran, edoxaban, rivaroxaban
NSAIDs Low risk: celecoxib, etodolac, ibuprofen, meloxicam, nabumetone, salsalate
High risk: flurbiprofen, indomethacin, ketorolac, meclofenamate, naproxen, oxaprozin, proxicam
SNRIs Desvenlafaxine, duloxetine, venlafaxine
SSRIs Citalopram, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline
NOA: novel oral anticoagulant, NSAID: nonsteroidal anti-inflammatory drug, SNRI: selective norepinephrine reuptake
inhibitor, SSRI: selective serotonin reuptake inhibitor.
Fig. 3. Coagulation pathway.
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agents include aspirin, NSAIDs, clopidogrel, and SSRIs,
and these drugs prevent initial clot formation by inhibiting
platelet adhesion and aggregation through slightly different
mechanisms. Some herbal drugs (e.g., ginko, garlic, ginger,
ginseng) have been shown to increase the risk of bleeding.
Since the combined use of different drugs may create drug-
drug interactions, it is recommended to monitor patients
closely for the first 5 days after prescribing antibiotics and
antifungal agents54). Moreover, bleeding may be associated
with concurrent use of clopidogrel and proton pump inhibitors
(PPIs) due to the inhibition of CYP2C19. Therefore, the
presence of bleeding should be detected through blood tests55).
ROLE OF IV IRON
Gombotz et al.56) suggested that the need for allogeneic
transfusion was predictable in 97.4% of cases by the
following factors: 1) level of anemia prior to surgery, 2)
volume of perioperative blood loss and 3) transfusion
trigger; therefore the assessment of preoperative hemoglobin
level was most important of all. A preoperative hemoglobin
level has been identified as the strongest predictor of the
need for transfusion and is related with an increase in
mortality. According to a study undertaken by Lasocki et
al.57), on 1,534 patients who underwent orthopedic surgery,
of all 217 patients with a preoperative anemic state, 97.7%
maintained an anemic state postoperatively, whereas all
1,317 patients with a non-anemic state preoperatively,
83.8% were switched to an anemic state postoperatively.
Furthermore, in a study on 7,759 patients who received
non-cardiac surgery, Beattie et al.58) reported that preoperative
anemia increased the risk of allogeneic transfusion and
90-day mortality.
When anemia is detected in when testing preoperative
hemoglobin levels, the cause of anemia should be identified.
Though malnutrition, chronic renal failure and others
should be considered, iron-deficiency is the leading cause
of anemia, accounting for the largest percentage. Iron
therapy is leveraged to treat iron deficiency anemia, and
a comparative studies on oral iron replacement and parenteral
iron replacement described the safety, convenience and
effective benefits of parenteral iron replacement59).
IV iron therapy reduces the risk of perioperative anemia
by conveniently and rapidly supplementing iron stores and
also lowers the risks of mortality and need for allogeneic
transfusions. Currently, a variety of iron supplements exist,
and because each medication has unique molecular structures
and varies in their iron content and absorption, instructions
for the proper use of each product should be taken into
account (Table 2). Potential adverse events following IV
iron injection are temporary hot flashes, chest compression,
headache, nausea, vomiting, mild fever, arthralgia and myalgia
associated with free iron toxicity, and hypersensitive reaction
caused by an immune response may occur60,61) (Table 3).
Multiple recent studies have demonstrated that preoperative
IV iron therapy significantly lowers the risk of allogeneic
transfusions and shortened the length of hospital stay62,63).
CONCLUSION
Patient blood management has improved clinical outcomes
following hip arthroplasty through the introduction of various
treatment options including preoperative assessment of
patients, anesthetic techniques, the use of TXA and others,
thereby reducing the need for allogeneic blood transfusion,
the risk of transfusion-related infection and the duration
of hospitalization. Further research is warranted in the
field of orthopedic surgery.
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